Journal
CLINICAL AND EXPERIMENTAL IMMUNOLOGY
Volume 166, Issue 2, Pages 154-163Publisher
WILEY
DOI: 10.1111/j.1365-2249.2011.04466.x
Keywords
chronic lymphocytic leukaemia; fludarabine; immunomodulation; T regulatory cells
Categories
Funding
- Medical Research Council [G0901755, G9818340B] Funding Source: researchfish
- MRC [G0901755] Funding Source: UKRI
- Medical Research Council [G0901755] Funding Source: Medline
Ask authors/readers for more resources
Advanced chronic lymphocytic leukaemia (CLL) is associated with profound immunodeficiency, including changes in T regulatory cells (T-regs). We determined the pattern of expression of forkhead box P3 (FoxP3), CD25, CD27 and CD127 and showed that the frequency of CD4(+)FoxP3(+) T cells was increased in CLL patients (12% versus 8% in controls). This increase was seen only in advanced disease, with selective expansion of FoxP3-expressing cells in the CD4(+)CD25(low) population, whereas the number of CD4(+)CD25(high)FoxP3(+) cells was unchanged. CD4(+)CD25(low) cells showed reduced expression of CD127 and increased CD27, and this regulatory phenotype was also seen on all CD4 T cells subsets in CLL patients, irrespective of CD25 or FoxP3 expression. Incubation of CD4(+) T cells with primary CLL tumours led to a sixfold increase in the expression of FoxP3 in CD4(+)CD25(-)T cells. Patients undergoing treatment with fludarabine demonstrated a transient increase in the percentage of CD4(+)FoxP3(+) T cells, but this reduced to normal levels post-treatment. This work demonstrates that patients with CLL exhibit a systemic T cell dysregulation leading to the accumulation of CD4(+)FoxP3(+) T cells. This appears to be driven by interaction with malignant cells, and increased understanding of the mechanisms that are involved could provide novel avenues for treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available